Esperion Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Esperion Therapeutics

27/02/2024 14:31

* Esperion Therapeutics Inc  ESPR.OQ  reported a quarterly
adjusted loss of 50 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -76 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 48 cents per
share. Wall Street expected results to range from -62 cents
to -35 cents per share.
    * Revenue rose 71.4% to $32.25 million from a year ago;
analysts
expected $28.70 million. 
    * Esperion Therapeutics Inc's reported EPS for the quarter
was a
loss of 50 cents​.
    * The company reported a quarterly loss of $56.34 million.
    * Esperion Therapeutics Inc shares had fallen by 12.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Esperion
Therapeutics Inc is $8.00 
This summary was machine generated from LSEG data February 27 at
02:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.48          -0.50          Missed
 Sep. 30 2023      -0.43          -0.37          Beat
 Jun. 30 2023      -0.61          -0.46          Beat
 Mar. 31 2023      -0.65          -0.79          Missed